Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line TIP after unfavorable tumor marker decline on BEP in poor-prognosis disseminated non-seminomatous germ cell tumors
2014-001270-33Phase 2Completed
- Sponsor
- Národný onkologický ústav
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide and cisplatin in non-seminomatous germ cell tumor (NSGCT) and germ cell tumor (GCT), sponsored by Národný onkologický ústav. Primary endpoint: Complete response rate. Started Apr 2015; status: completed.
02
Drugs
paclitaxelifosfamidecisplatin
03
Conditions
non-seminomatous germ cell tumor (NSGCT)germ cell tumor (GCT)
Beyond the preview
Go deeper on 2014-001270-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001270-33.